Home Cart Sign in  
Chemical Structure| 113104-25-9 Chemical Structure| 113104-25-9

Structure of NSC 228155
CAS No.: 113104-25-9

Chemical Structure| 113104-25-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NSC228155 can enhance the tyrosine phosphorylation of EGFR via binding to the dimerization domain II. It blocks KIX-KID interaction as well (IC50 = 0.36 μM).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NSC 228155

CAS No. :113104-25-9
Formula : C11H6N4O4S
M.W : 290.25
SMILES Code : [O-][N+]1=CC=CC=C1SC2=CC=C(C3=NON=C32)[N+]([O-])=O
MDL No. :MFCD30742994
InChI Key :ICCFXXDUYSPKOL-UHFFFAOYSA-N
Pubchem ID :313619

Safety of NSC 228155

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of NSC 228155

RTK
JAK-STAT
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SW620 cells 100 µM 12 hours NSC228155 increased EGFR and ERK1/2 phosphorylation and almost completely restored ABHD11-AS1-mediated attenuation of EGFR and ERK1/2 phosphorylation. Int J Oncol. 2025 Mar;66(3):20.
HCT116 cells 100 µM 12 hours NSC228155 increased EGFR and ERK1/2 phosphorylation and almost completely restored ABHD11-AS1-mediated attenuation of EGFR and ERK1/2 phosphorylation. Int J Oncol. 2025 Mar;66(3):20.
A549 2 µM NBD treatment led to activation of EGFR at Y1068 phosphorylation site and its downstream, STAT/AKT/ERK. However, when co-treated with Daidzein and Gefitinib combination NBD compound failed to activate EGFR and its downstream effectors. Int J Biol Sci. 2022 May 16;18(9):3636-3652.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.45mL

0.69mL

0.34mL

17.23mL

3.45mL

1.72mL

34.45mL

6.89mL

3.45mL

References

 

Historical Records

Categories